Crizotinib, an inhibitor of anaplastic lymphoma kinase (ALK), MET, and ROS1, is approved for treatment of patients with ALK-positive or ROS1-positive advanced non-small-cell lung cancer (NSCLC). However, ALK rearrangements are also implicated in other malignancies, including anaplastic large-cell lymphoma and inflammatory myofibroblastic tumors (IMTs). In this ongoing, multicenter, single-arm, open-label phase 1b study (PROFILE 1013; NCT01121588), patients with ALK-positive advanced malignancies other than NSCLC were to receive a starting dose of crizotinib 250 mg twice daily. Primary endpoints were safety and objective responses based on Response Evaluation Criteria in Solid Tumors version 1.1 or National Cancer Institute International Response Criteria. Forty-four patients were enrolled (lymphoma, n 5 18; IMT, n 5 9; other tumors, n 5 17). The objective response rate was 53% (95% confidence interval [CI], 28-77) for lymphoma, with 8 complete responses (CRs) and 1 partial response (PR); 67% (95% CI, 30-93) for IMTs, with 1 CR and 5 PRs; and 12% (95% CI, 2-36) for other tumors, with 2 PRs in patients affected by colon carcinoma and medullary thyroid cancer, respectively. The median duration of treatment was almost 3 years for patients with lymphoma and IMTs, with 2-year progression-free survival of 63% and 67%, respectively. The most common treatmentrelated adverse events were diarrhea (45.5%) and vision disorders (45.5%), mostly grade 1. These findings indicate strong and durable activity of crizotinib in ALK-positive lymphomas and IMTs. The safety profile was consistent with the known safety profile of crizotinib even with long-term treatment.
| I N TR ODU C TI ON
Activating mutations or translocations of the anaplastic lymphoma kinase (ALK) oncogene have been recurrently identified in several cancer types, including non-small-cell lung cancer (NSCLC), anaplastic large-cell lymphoma (ALCL), inflammatory myofibroblastic tumors (IMTs), and neuroblastoma. [1] [2] [3] Activation of the ALK gene usually occurs through chromosomal rearrangement, resulting in the placement of one of several different 5ʹ fusion partners and their associated promoter regions upstream of the ALK kinase domain. ALK point mutations and possibly overexpression of ALK can also lead to activation of ALK signaling in human tumors. [4] [5] [6] ALCL is a rare form of non-Hodgkin lymphoma (NHL), usually consisting of large neoplastic cells with abundant cytoplasm and pleomorphic nuclei, with a translocation involving the ALK gene, and expression of ALK protein and CD30. It accounts for 3% of adult and 10%-15% of pediatric NHL cases. [7] [8] [9] ALCL may be effectively treated using intensive chemotherapy regimens (e.g. cyclophosphamide, doxorubicin, vincristine, and prednisone [CHOP]) 10, 11 but at the cost of early and long-term toxicities. 8, 12 In addition, if relapse occurs after first-line treatment, ALCL has a poor prognosis and tends to follow a very aggressive clinical course. 13 IMTs are a rare type of mesenchymal neoplasm composed of a variable mixture of myofibroblasts and inflammatory infiltrates that can occur throughout the body, predominantly in the mesentery, retroperitoneum, and pelvis. ALK rearrangements have been implicated in giving rise to oncogenic fusion proteins in 50% of IMTs. [14] [15] [16] [17] [18] In addition, activating ALK mutations are found in about 7%-9% of cases of neuroblastoma, a childhood cancer of the developing nervous system. 19, 20 Single-agent clinical protocols facilitate rapid enrollment of molecularly profiled patients with genetic alterations linked to targeted therapies, and early signs of clinical activity in such trials provide opportunities for detection of new indications using a patient-sparing design that could lead to subsequent confirmatory trials. 21 Crizotinib is a potent, orally administered, small-molecule tyrosine kinase inhibitor of ALK, MET, and ROS1 receptor tyrosine kinases. 22, 23 Currently, crizotinib has received marketing authorization approvals globally for the treatment of ALK-positive advanced NSCLC in over 90
countries. In 2016, crizotinib was also approved in the United States and European Union for the treatment of patients with advanced NSCLC whose tumors are ROS1-positive. 24 Here, we report the results of the PROFILE 1013 study that evaluated the safety and antitumor activity of single-agent, oral crizotinib among patients with advanced ALCL, IMT, or other advanced ALKpositive malignancies different from NSCLC. 
| M E TH ODS

| Endpoints
The primary endpoints were objective response rate (ORR) based on RECIST v1.1 or the NCI International Response Criteria, the type, incidence, severity, seriousness, and relationship to study medications of AEs, and laboratory abnormalities. Secondary endpoints included progression-free survival (PFS), overall survival (OS) at 6 months and 1 and 2 years, OS, and duration of response (DOR). 
| Trial oversight
| Statistical analysis
The sample size for this study was determined empirically based on expected small numbers of patients in the population of interest, and it was anticipated that approximately 40 patients would be enrolled. The study population for all analyses (except tumor response-related endpoints) included patients enrolled in the study who received at least one dose of crizotinib. For response-related endpoints, enrolled patients who received at least one dose of crizotinib also had to have an adequate baseline tumor assessment.
Descriptive statistics were used to summarize patient characteristics, treatment administration, antitumor activity, and safety. The ORR was summarized with the corresponding exact 2-sided 95% confidence interval (CI) calculated using a method based on the F distribution. Secondary time-to-event endpoints were summarized using Kaplan-Meier methods. The data cutoff date was March 4, 2016. Data were summarized for the overall patient population, as well as separately for antitumor activity in the ALCL, IMT, and "other tumors" patient groups.
| R E SU LTS
| Patients
From March 2011 through October 2013, a total of 44 patients were enrolled in the study (lymphoma, n 5 18; IMT, n 5 9; and other tumors, n 5 17). Demographic characteristics are shown in Table 1 , and patients' diagnoses in the other tumors group are shown in Supporting Information Table S1 . All enrolled patients were either white or Asian in nearly equal proportions (Japanese, Korean, or Chinese).
| Antitumor activity 3.2.1 | Lymphoma group
In the lymphoma group, 17 of 18 patients were evaluable for response (Table 2) , as 1 patient was retrospectively found not to have measurable disease. The patient was followed for antitumor activity based on positive RT-PCR status for NPM-ALK, which predicts a poor prognosis, 26 and became RT-PCR negative within 4 months of treatment; this patient was still on treatment and relapse-free at the data cutoff (at cycle 74), after more than 4 years on crizotinib. years with all but 1 patient still in response or ongoing at the time of data cutoff (Supporting Information Figure S1 ). In addition, 3 patients (17.6%) had stable disease (SD), including one lasting over 3.5 years and ongoing at data cutoff in a patient with diffuse large B-cell lymphoma (DLBCL). Median PFS had not been reached (Figure 1 disease-free at the data cutoff, after more than 4 years on crizotinib.
| IMT group
All patients with IMT were evaluable for response (Table 2) . Patients in the IMT group had an ORR of 66.7% (95% CI, 29.9-92.5), which comprised 1 CR and 5 PRs. Three patients are still in response, with responses lasting over 2 years, and these patients remain in follow-up (Supporting Information Figure S1 ). In addition, 3 patients (33.3%) had SD. Median PFS was not reached in the IMT group (Figure 1 ) because of the small number of events (33%) and 55.6% of patients with IMT who remain in follow-up for progression. PFS at 2 years was 66.7%
(95% CI, 28.2-87.8). In addition, median OS was not reached as 66.7%
of patients with IMT were alive at the data cutoff (Figure 2 ).
| "Other tumors" group
All patients in the "other tumors" group were evaluable for response ( (Figure 2 ).
| Safety
At the time of data cutoff, the duration of crizotinib treatment ranged Table S2 ), and treatment-related AEs (TRAEs) occurred in a total of 39 patients (88.6%) ( Table 3) . Mild-to-moderate diarrhea and vision disorder were the most common TRAEs reported (both 45.5%), most of which were grade 1.
Overall, 9 patients (20.5%) experienced an SAE considered to be related to crizotinib treatment ( Table 3 ). The most common SAE considered possibly related to treatment was grade 4 blood creatine phosphokinase increase reported in 3 patients (6.8%), all in clinical response and concurrent with strenuous physical activity that is known to cause brisk elevations of creatine phosphokinase levels.
27
Grade 5 AEs considered by the investigator as related to treatment occurred in 2 patients: cerebral infarction in a patient with unknown primary tumor and multiple brain metastases, concurrent with disease progression, and interstitial lung disease in a patient with nasopharyngeal carcinoma. Subsequent review by an independent radiology committee, consisting of a pulmonologist, radiologist, and oncologist, indicated that this event was aspiration pneumonia and not related to the study drug.
Permanent discontinuation of crizotinib associated with TRAEs occurred in the 2 patients with cerebral infarction (2.3%) and interstitial lung disease (2.3%). Disease progression led to permanent discontinuation from treatment in 50% of patients.
Overall, 21 patients died during the study. Seventeen patients died because of disease progression, 1 patient died from interstitial lung disease/aspiration pneumonia, and 1 patient died because of cerebral infarction (the latter 2 as previously described). During long-term follow-up, 1 patient died because of small bowel obstruction and hernia complication (13 months after treatment discontinuation) and 1 patient's cause of death (10 months after treatment discontinuation) remained unknown.
| D ISC USSION
Crizotinib has been shown to be superior to standard chemotherapy in previously treated and untreated patients with ALK-positive advanced NSCLC 28, 29 and has previously been shown to have therapeutic activity Table S3 . Deep vein thrombosis (grade 3; n 5 1) was concurrent with a course of corticosteroids; myocardial ischemia (grade 3) and cardiac failure (grade 4) occurred in the same patient, who had preexisting hypertension and coronary artery disease. These grade 3 SAEs were considered possibly treatment-related by the investigator; however, their relationship to concomitant medications, coexisting medical conditions, or tumor progression could not be clearly established. AE, adverse event; CPK, creatine phosphokinase; CTCAE, Common Terminology Criteria for Adverse Events; SAE, serious adverse event. Sustained and durable responses to crizotinib in lymphoma were observed in another study performed in 26 pediatric patients with relapsed or refractory ALK-positive ALCL, which represent an update of a previous publication. 33 Although a high response rate of 90% was observed in the Children's Oncology Group study, one-half of patients ultimately received stem cell transplantation, 34 thus rendering the evaluation of the long-term effects of crizotinib in this population problematic.
In PROFILE 1013, this was not a confounding factor as only 1 responder underwent bone marrow transplantation and was censored at that time.
Previous reports have shown that crizotinib has antitumor activity in patients with unresectable ALK-positive IMTs 34 as well as in those with refractory ALK-positive IMT. 33, 38 A case report of a patient with ALKpositive IMT documented complete radiographic remission 2 years after initiating crizotinib treatment. 39 The results of our study indicate a marked antitumor activity, with nearly two-thirds of objective responses lasting >2 years and a PFS at 2 years of 67%. The durable responses observed in this small set of patients further support the National Comprehensive Cancer Network's recommendation of crizotinib as a treatment for IMTs with an ALK rearrangement 40 and suggest that ALK testing should be routinely performed in all patients with IMT. In contrast, a low level of response was observed in the "other tumors" group, which included a variety of ALK-positive tumors. Potential reasons for lack of clinical activity include differences in ALK signaling events in different tumor types (i.e., "early" vs "late" events during tumor progression), differing tumor types, and genetics of the tumor cell, which may affect the response to ALK tyrosine kinase inhibitors. 41 In addition, point mutations permitted in this study, for example F1174L and F1245C (common ALK-activating mutations seen in neuroblastoma), have been shown to confer resistance to crizotinib in neuroblastoma and other cancers. 33, 42, 43 MYCN overexpression has also been associated with resistance to ALK inhibitors. 44 However, in this subgroup, 1 patient with mucinous carcinoma of the colon achieved a long-lasting response of almost 2 years, 1 patient with medullary thyroid carcinoma also responded to crizotinib with a response duration of 4 months, and 1 patient with neuroblastoma had SD for 19 months, suggesting that ALK alterations may act as an oncogenic driver and can potentially be targeted in other malignancies.
Previously, safety data were reported from studies of crizotinib with median treatment durations of only 10.9 months, 28 which is substantially less than the median treatment duration in the ALCL and IMT groups in this study (35 and 33 months, respectively) . The treatment durations (up to 57 months) in this study are currently the longest reported in the literature in adult patients and therefore provide new information about the long-term safety of crizotinib.
Crizotinib was generally well tolerated; the safety profile observed was similar to that reported previously with crizotinib, and no new safety signals were identified. 28, 29, 45 Limitations of this study include its single-arm, open-label design, small patient population, and the heterogeneity of the patients' tumors.
In conclusion, this study indicated strong and durable activity of crizotinib in ALK-positive lymphomas and IMTs. Treatment duration was much longer than usual treatment in patients with NSCLC, and the safety profile was consistent with the known safety profile of crizotinib, even with long-term treatment.
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